Overview

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)

Status:
Completed

Trial end date:
2020-05-28

Target enrollment:

Participant gender:

Summary

This is a long-term, open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period in children with Alagille Syndrome (ALGS) designed to evaluate the safety and efficacy of LUM001 (Also known as maralixibat or MRX).

Phase:

Phase 2

Details

Lead Sponsor:

Mirum Pharmaceuticals, Inc.
Shire

Collaborator:

Lumena, Inc.